Develop Chronic Wound Articles & Analysis
3 news found
Pravibismane exhibits broad-spectrum, potent in vitro activity against chronic respiratory infection and chronic wound relevant pathogens and their biofilms including NTM, multidrug resistant P. aeruginosa and MRSA. ...
About Microbion Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering unique potential to address the unmet needs of ...
“Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and prevent biofilm-related infections, since biofilm contamination is a hallmark characteristic of chronic foot ulcer infections. ...